Peter Menziuso Named EVP and President, BD Interventional
BD (NYSE: BDX) appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BD (NYSE: BDX) appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, 2026. He brings 30+ years of global healthcare leadership and previously led a $5 billion Johnson & Johnson Vision business across commercial, R&D, supply chain and other functions.
BD indicates his experience in market leadership, team building and operational excellence is expected to support continued growth and strong performance within BD Interventional.
Positive
- Experienced leader appointed EVP and president of BD Interventional effective June 1, 2026
- Previously led a $5 billion global Johnson & Johnson Vision business
- More than 30 years of global healthcare leadership experience
Negative
- None.
Details
News Market Reaction – BDX
On May 18, the day this news came out, BDX closed 0.78% below the previous close.
Data tracked by StockTitan Argus for the May 18 session.
Key Figures
- Leadership experience
- more than 30 years
- Global healthcare leadership background of Peter Menziuso
- Prior business size
- $5 billion
- Global Johnson & Johnson Vision business led by Menziuso
- Effective date
- June 1
- Start date as EVP and President, BD Interventional
Historical Context
-
Named long-time BD executive Vitor Roque as permanent chief financial officer.
-
Reported Q2 FY2026 revenue growth, executed ASR, raised adjusted EPS guidance.
-
Announced AI-powered medication management collaboration with Wellstar using BD platforms.
-
Received multiple industry recognitions for employee health, well-being and workforce programs.
-
Launched CentroVena One system for central line insertion with FDA 510(k) clearance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
r&d technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth through disciplined execution. He most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a
Throughout his career, Menziuso has been recognized for strengthening market leadership, building high‑performing teams and translating strategy into sustained performance through commercial rigor and operational excellence. His global leadership experience, coupled with his customer obsession and ability to lead at scale position him well to accelerate execution and deliver continued growth for BD Interventional.
"BD Interventional has a strong track record of performance, and Peter is the right leader to build on that momentum and continue delivering results," said Tom Polen, chairman, CEO and president of BD. "Peter brings a strong combination of strategic leadership and operational discipline. He is grounded in delivering for customers and patients, building strong teams and driving consistent performance, positioning the business for sustained growth and continued strength across the portfolio."
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors |
Megan Dubrowski | Shawn Bevec SVP, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/peter-menziuso-named-evp-and-president-bd-interventional-302774280.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.